It is more important than ever to connect and share ideas. The Law Over Lunch series offers FDLI members the exclusive opportunity to engage in facilitated virtual discussions over lunch on topics of interest to the food and drug law community. This event features unique and co-occurring discussion groups, limited to ten attendees to encourage fruitful conversation. This member-only benefit is a chance to closely learn from, educate, and network with other professionals in the field on new and pertinent topics.
Please only sign up for one discussion as they will take place at the same time.
Table Topics and Facilitators
FDA-Regulated Start-ups and Social Media
Brigid Bondoc, Of Counsel
Morrison and Foerster, LLP
Food and Food Contact Safety: Evolving Environmental Challenges
Sam Jockel, Senior Associate
Alston & Bird LLP
and Greg Berlin, Senior Associate
Alston & Bird LLP
Should the Oncology Center of Excellence Model Be Utilized in Other Disease Areas?
Clay Alspach, Principal
Leavitt Partners, LLC
BRIGID BONDOC is a food, drug, and medical device lawyer who counsels life sciences companies on a wide range of US Food & Drug Administration pre- and post-market regulatory issues. Brigid focuses on medical device, digital health, and in vitro diagnostic companies, as well as other companies whose radiation-emitting electronic products are regulated by FDA’s Center for Devices and Radiological Health. She has advised innovative product developers and manufacturers on key threshold FDA regulatory questions, and regularly advises established life sciences companies on issues such as clinical trials regulation, product approvals and clearances, advertising and promotional claims, and adverse event reporting obligations. Brigid regularly assists clients in developing strategies for approval and marketing and in identifying and mitigating regulatory risks. She also handles challenges to competitor advertising before the National Advertising Division and has served as FDA counsel in product liability cases, civil litigation, international arbitration, and FDA enforcement proceedings. Brigid is a graduate of the University of Tulsa, where she earned her BS in biochemistry before attending law school at Stanford Law School.
SAMUEL D. JOCKEL is a senior associate in Alston & Bird’s Litigation & Trial Practice Group. Sam focuses his practice on regulatory, policy, and litigation matters involving food, cosmetics, dietary supplements, and drugs.
GREG BERLIN is a senior associate with Alston & Bird’s Environment, Land Use & Natural Resources Group. He focuses his practice on high-stakes environmental litigation and investigations, including defense against government enforcement actions, citizen suits, and natural resource damage claims. Greg has extensive experience helping Fortune 500 companies in the energy, retail, food, and manufacturing industries strategically resolve contamination, environmental compliance, and enforcement matters, often achieving summary dismissal or early settlements. He has defended actions in federal and state courts, including those arising under the Endangered Species Act, Clean Water Act, Porter-Cologne Water Quality Control Act, NEPA, and CEQA. Greg also advises, defends, and performs internal investigations on behalf of companies with issues concerning emerging contaminants, including PFAS contamination. Greg also represents clients in hundreds of Proposition 65 matters – both pre-emptively to ensure compliance and responsively to aggressively defend private enforcement actions. Greg received his JD, cum laude, from the University of California, Hastings College of Law, with a certificate in environmental law. He served as the executive symposium editor of the Hastings Law Journal and a judicial extern to the Hon. Edward M. Chen of the US District Court for the Northern District of California.
CLAY ALSPACH is a principal based in Washington, D.C. Clay specializes in health care policy and advocacy related to the Food and Drug Administration, health information technology, Medicare Parts B, C, and D, Medicaid, private health insurance, and the Affordable Care Act. Prior to joining Leavitt Partners, Clay served as Chief Health Counsel for Chairman Fred Upton of the U.S. House of Representatives Energy and Commerce Committee. During seven years with the committee, he managed, provided strategic direction, and served as the principal representative for the committee on all of its health care-related work. Clay spearheaded legislative initiatives that successfully reformed the SGR (MACRA), reauthorized FDA user fees (FDASIA), and established a national system for drug supply chain security (Drug Quality and Security Act). Clay also led the committee’s legislative accomplishments on biopreparedness and security, public and private medical research, controlled substance and DEA matters, and several other public health initiatives. Most recently, Clay led the committee’s work on the 21st Century Cures Act. Prior to this service for the committee, Clay clerked for the Honorable Ronald L. Buckwalter of the U.S. District Court for the Eastern District of Pennsylvania and worked as a litigator in private law practice. He also worked as a legislative clerk at the committee from 1999 to 2000 under Chairman Thomas J. Bliley (R-VA). Clay received his bachelors of arts cum laude from the University of Richmond and holds a juris doctorate from the University of Texas at Austin.July 21, 2022
12:00-1:00 PM ET
Registration is open to FDLI members only and is first come, first served.
This is a complimentary virtual event.
Please only sign up for one discussion as they will take place at the same time.
For questions, please contact Tess Garraty.
